Welcome to our dedicated page for Cardio Diagnostics Holdings SEC filings (Ticker: CDIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardio Diagnostics Holdings, Inc. filings document a Nasdaq-listed medical technology company with common stock under CDIO and redeemable warrants under CDIOW. The company identifies as an emerging growth company and reports formal disclosures tied to its precision cardiovascular medicine business, including clinical data, reimbursement progress, corporate updates, and strategic priorities furnished through Regulation FD materials.
Its SEC record also includes proxy and annual meeting disclosures covering stockholder voting matters, board and governance items, and meeting procedures. Material-event filings provide updates on corporate communications and security-holder actions, while proxy statements describe proposals submitted to holders of the company’s common stock.
Paul Burton, a director of Cardio Diagnostics Holdings, Inc. (CDIO), exercised stock options on 09/30/2025 to acquire 1,559 shares at an exercise price of $4.01 per share. The options are exercisable immediately and expire on 09/30/2035. Following the reported transaction, Mr. Burton beneficially owns 4,953 shares of common stock. The Form 4 was filed via signature by Elisa Luqman as attorney-in-fact on 10/03/2025. The filing identifies the reporting person as a director and shows the ownership form as direct.
Cardio Diagnostics Holdings, Inc. will hold its 2025 annual meeting virtually on October 15, 2025 at 10:00 a.m. Central Time for holders of record as of August 25, 2025. As of the record date the company reported 1,763,129 shares of common stock outstanding. The board recommends voting FOR three proposals: (1) election of seven director nominees for one-year terms; (2) approval to issue shares and/or convertible/exercisable securities in one or more non-public transactions equal to 20% or more of outstanding common stock under Nasdaq Rule 5635(d); and (3) ratification of Prager Metis CPA's LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The proxy discloses parameters for the 2025 Issuance Proposal: a maximum of 1,666,666 shares (post 1-for-30 reverse split), a maximum aggregate dollar amount of $10.0 million, a maximum discount to market of 25%, and an intended issuance timeframe not to exceed three months from stockholder approval (with potential Nasdaq approval to extend to six months).
Cardio Diagnostics Holdings, Inc. is soliciting proxies for a virtual Annual Meeting on October 15, 2025 where stockholders will vote on three items: election of seven director nominees (including the CEO and CMO, both co‑founders), ratification of Prager Metis CPA's LLC as the company’s independent registered public accounting firm, and approval to permit future non‑public issuances of Common Stock or convertible/exercisable securities equal to 20% or more of outstanding shares in accordance with Nasdaq Rule 5635(d).
The 2025 Issuance Proposal requests authorization to issue up to 1,666,666 shares (post 1‑for‑30 reverse split), with a maximum aggregate of $10.0 million, a maximum 25% discount to market, and a proposed issuance window of up to three months (extendable to six months with Nasdaq approval). The filing states the company has raised approximately $14.8 million and issued 1,054,841 shares under its ATM program and that it continues to need additional capital to maintain operations. The Board recommends voting FOR all proposals. The proxy also discloses governance details including independent committee composition and an audit committee financial expert.